Overview

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Status:
Not yet recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study is a one-arm, open, multicenter phase 1b/2 clinical trial of YY-20394 combined with GEMOX second-line or above in patients with relapsed and/or refractory diffuse large B-cell lymphoma. YY-20394 combined with GEMOX was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of GEMOX was treated according to clinical standards.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Shanghai YingLi Pharmaceutical Co. Ltd.

Treatments:

Gemcitabine
Oxaliplatin